Latest stories on MOLN
Molecular Partners selects MP0730 as lead Radio-DARPin candidate
The Fly61 · neutralproduct/pr
Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70
GlobeNewswire58 · neutralproduct/pr
Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70
Business Insider58 · neutralproduct/pr
Clear Street transfers coverage on Molecular Partners, keeps Buy rating
The Fly61 · neutralanalyst
Molecular Partners GAAP EPS of -CHF0.70
Seeking Alpha34 · bearishearnings
Molecular Partners Starts Phase 2 TACTIC Trial of MP0317 in Front-Line Cholangiocarcinoma
TipRanks56 · neutralproduct/pr
Molecular Partners Advances Radio-DARPin Cancer Pipeline With MP0712 Trial and Upcoming MP0726 Imaging
TipRanks63 · neutralproduct/pr
Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics | MOLN Stock News
StockTitan56 · neutralproduct/pr
Molecular Partners and Orano Med Dose First Patients in MP0712 Phase 1/2a Trial
TipRanks63 · neutralproduct/pr
Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712 | MOLN Stock News
StockTitan63 · neutralproduct/pr
Molten Ventures Ceo Boosts Stake With 49700 Share Purchase
TipRanks63 · neutralgeneral
Molecular Partners Starts Dosing DLL3 Radio-DARPin MP0712, Highlights Program at ASCO and SNMMI 2026
TipRanks63 · neutralproduct/pr
Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit | MOLN Stock News
StockTitan56 · neutralproduct/pr